Acute Pulmonary Embolism (PE)NCT07107347
Assessment of Right Ventricular Function After Acute Pulmonary Embolism: a Comparison of Speckle Tracking Strain and Conventional Echocardiographic Parameters
An observational study of Acute Pulmonary Embolism (PE), run by Assiut University at 1 site in Egypt.
Trial summary
Echocardiographic Assessment: Performed within 24h of PE diagnosis Conventional parameters: TAPSE, RV FAC, RV/LV ratio, tricuspid S', PASP STE parameters: RV free wall longitudinal strain (RVFWS), global longitudinal strain (GLS) if feasible All measurements averaged over 3 cardiac cycles (sinus) or 5 (AF) Follow-up… Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- Acute Pulmonary Embolism (PE)
- How many people
- 100 participants
- Where
- 1 siteEgypt
- Study dates
- Sep 2025to Mar 2028
- Phase
- Observational
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Study population: patients aged more than 18 years old with confirmed pulmonary embolism
Who may be able to join
- Adults ≥18 years.
- Confirmed acute PE (via CT pulmonary angiography).(4,6)
- Echocardiography performed within 24 hours of diagnosis.
Who cannot join
- Pre-existing significant RV dysfunction (e.g., due to chronic pulmonary hypertension, cor pulmonale or congenital heart disease).
- History of coronary artery disease.
- Impaired LV systolic function, ejection fraction <50%.
- Moderate to severe valvular heart disease.
- Prior document of an episode of pulmonary embolism.
- Poor acoustic window.
- Hemodynamic instability
Trial locations and contacts
1 site in 1 country. Contact the study team or a site near you to ask about taking part.
Egypt1 site
Assiut University Hospital
Asyut, Asyut Governorate, 25361
Doaa Roshdy, 01024588594, doaa.elenany@yahoo.com
About this study
Official title: Assessment of Right Ventricular Function for Diagnosis and Prognosis After Acute Pulmonary Embolism: a Comparison of Speckle Tracking Strain and Conventional Echocardiographic Parameters
Echocardiographic Assessment:
Performed within 24h of PE diagnosis Conventional parameters: TAPSE, RV FAC, RV/LV ratio, tricuspid S', PASP STE parameters: RV free wall longitudinal strain (RVFWS), global longitudinal strain (GLS) if feasible All measurements averaged over 3 cardiac cycles (sinus) or 5 (AF)
Follow-up data:
ICU/hospital LOS Need for vasopressors/mechanical ventilation In-hospital and 30-day mortality
Read the detailed description
the study targets patient with acute pulmonary embolism confirmed by CTPA, without hemodynamic instability. within the first 24 hours echocardiography will be conducted, assessment of RV function by conventional measures eg, TAPSE, S', FCA and speckle tracking strain echocardiography.
compare the results and its sensitivity in prediction of clinical outcomes, that will be assessed by follow up the patients for one month regarding length of hospital stay, oxygen/ventilatory support, hemodynamics support and 30 day mortality.
- Conditions
- Acute Pulmonary Embolism (PE)
- Keywords
- acute pulmonary embolism (PE), STE, right ventricle strain, speckle tracking strain
What is being measured
The primary outcome is the main question the study is designed to answer.
Primary (main): Composite of in-hospital mortality, ICU admission >7 days, or need for mechanical circulatory/ventilatory support.
Measured: 30 day follow up
Secondary outcomes (1)
Secondary outcome: Each individual component; echocardiographic parameters as predictors.
Measured: 30 day follow up
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted6 Aug 2025
- Study startSep 2025 (estimated)
- Primary completionSep 2027 (estimated)
- Study completionMar 2028 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Acute Pulmonary Embolism (PE)Studies of the same condition, open and under way.
- More trials run by Assiut UniversityThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Cohort
- Time perspective
- Prospective
- Enrolment
- 100 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Assiut University
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Doaa Roshdy Abdul Satar Mohamed, Assiut University
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07107347
- Sponsor's protocol ID
- STE in pulmonary embolism
- Status last verified
- Jul 2025
- First submitted
- 30 Jul 2025
- Last updated
- 14 Aug 2025
- Results posted
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
Study at a glance
From the registry record, last updated by the sponsor on 14 Aug 2025. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Assessment of Right Ventricular Function for Diagnosis and Prognosis After Acute Pulmonary Embolism: a Comparison of Speckle Tracking Strain and Conventional Echocardiographic Parameters
- ClinicalTrials.gov ID
- NCT07107347
- Acronym / sponsor ID
- STE in pulmonary embolism
- Conditions
- Acute Pulmonary Embolism (PE)
- Keywords
- acute pulmonary embolism (PE), STE, right ventricle strain, speckle tracking strain
- Study type
- Observational
- Recruitment status
- Not yet recruiting
- Enrolment
- 100 participants (estimated)
- Lead sponsor
- Assiut UniversityUniversity, hospital or other
- Study start
- Sep 2025 (estimated)
- Primary completion
- Sep 2027 (estimated)
- Study completion
- Mar 2028 (estimated)
- First posted
- 6 Aug 2025 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Echocardiographic Assessment:
Performed within 24h of PE diagnosis Conventional parameters: TAPSE, RV FAC, RV/LV ratio, tricuspid S', PASP STE parameters: RV free wall longitudinal strain (RVFWS), global longitudinal strain (GLS) if feasible All measurements averaged over 3 cardiac cycles (sinus) or 5 (AF)
Follow-up data:
ICU/hospital LOS Need for vasopressors/mechanical ventilation In-hospital and 30-day mortality
Detailed description
the study targets patient with acute pulmonary embolism confirmed by CTPA, without hemodynamic instability. within the first 24 hours echocardiography will be conducted, assessment of RV function by conventional measures eg, TAPSE, S', FCA and speckle tracking strain echocardiography.
compare the results and its sensitivity in prediction of clinical outcomes, that will be assessed by follow up the patients for one month regarding length of hospital stay, oxygen/ventilatory support, hemodynamics support and 30 day mortality.
Study design
- Observational model
- Cohort
- Time perspective
- Prospective
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
- Study population
- patients aged more than 18 years old with confirmed pulmonary embolism
Key inclusion criteria (3 listed)
- Adults ≥18 years.
- Confirmed acute PE (via CT pulmonary angiography).(4,6)
- Echocardiography performed within 24 hours of diagnosis.
Key exclusion criteria (7 listed)
- Pre-existing significant RV dysfunction (e.g., due to chronic pulmonary hypertension, cor pulmonale or congenital heart disease).
- History of coronary artery disease.
- Impaired LV systolic function, ejection fraction <50%.
- Moderate to severe valvular heart disease.
- Prior document of an episode of pulmonary embolism.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Primary outcome
Primary (main): Composite of in-hospital mortality, ICU admission >7 days, or need for mechanical circulatory/ventilatory support.
Time frame: 30 day follow up
1 secondary outcome
Secondary outcome: Each individual component; echocardiographic parameters as predictors.
Time frame: 30 day follow up
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 14 Aug 2025.
Related trials for Acute Pulmonary Embolism (PE)
Not yet recruiting
Pilot Study Evaluating Catheter Directed Thrombolysis Device in Acute Intermediate Risk Pulmonary Embolism
Pulmonary Embolism (PE), Pulmonary Embolism With Right Ventricle Enlargement
Not yet recruiting
CTEPH Differential Diagnosis Assisted by Enhanced Large Language Model Support
Chronic Thromboembolic Pulmonary Hypertension (CTEPH), Acute Pulmonary Embolism (PE)
RecruitingObservational study
A Real-World Study of EkoSonic Endovascular System in Chinese Populations With Acute Pulmonary Embolism
Acute Pulmonary Embolism
RecruitingObservational study
Pulmonary Embolism Registry From Short-Term Emergency to Long-Term Follow-Up and Surveillance
Venous Thromboembolism (VTE), Chronic Thromboembolic Pulmonary Hypertension
RecruitingObservational study
Repeated Examinations for Typing Pulmonary Embolism
Pulmonary Embolism (Diagnosis), Pulmonary Embolism Acute
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Acute Pulmonary Embolism (PE), run by Assiut University at 1 site in Egypt.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 3 inclusion and 7 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: opening soon, as of the sponsor's last update on 14 Aug 2025. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Egypt. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Doaa Roshdy, assistant lecturer (+201024588594, doaa.elenany@yahoo.com), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Primary (main): Composite of in-hospital mortality, ICU admission >7 days, or need for mechanical circulatory/ventilatory support. (time frame: 30 day follow up). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 14 Aug 2025.